Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Executive Summary

AstraZeneca agreed to partner two important oncology assets – Lynparza and selumetinib – with Merck after disappointing Imfinzi MYSTIC data. Merck will pay $1.6bn up front to get its hands on a PARP inhibitor, even though it previously owned one.

Advertisement

Related Content

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round
SOLO-1 Lynparza Data In First-Line Ovarian Cancer Seen Boosting AstraZeneca's PARP Edge
AstraZeneca Looks To Deliver On Its Promises In Oncology
AstraZeneca's Imfinzi, Lynparza On Track To India Debut
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer
AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon
Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study
Another Late-Stage Failure For AstraZeneca's Selumetinib

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel